Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma

Anita Gupta, Hanlin L. Wang, Maria Luisa Policarpio-Nicolas, Maria S. Tretiakova, Veronica Papavero, Michael R. Pins, Zhong Jiang, Peter A. Humphrey, Liang Cheng, Ximing J. Yang

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Nephrogenic adenoma is a benign lesion composed of small glandular structures that develops along the urothelium with uncertain pathogenesis. Some investigators believe that nephrogenic adenoma develops by a metaplastic process in response to injury to the urothelium, while others believe that it arises from detached renal tubules. Nephrogenic adenoma may be present in the prostatic urethra and morphologically mimic prostatic adenocarcinoma. Alpha-methylacyl-coenzyme A racemase (AMACR), a recently identified prostate cancer marker, is typically negative in normal urothelium and prostatic glands, and positive in distal convoluted renal tubules in addition to prostatic adenocarcinomas. Therefore, evaluation of AMACR expression in nephrogenic adenoma will have significance in the pathologic diagnosis and in understanding pathogenesis of this lesion. We studied 38 nephrogenic adenomas by clinical, histologic, and immunohistochemical analyses for AMACR (P504S) and high molecular weight cytokeratin (34βE12). Twenty-two of 38 nephrogenic adenomas (58%) demonstrated strong cytoplasmic positivity for AMACR, ranging from patchy, focal to diffuse staining. In addition, 16 of 26 (62%) nephrogenic adenomas were negative for 34βE12. To our knowledge, this is one of the first report of a completely benign lesion, which can be found in the prostate, showing strong AMACR immunoreactivity. Our findings suggest using caution when interpreting positive AMACR immunostaining in prostatic specimens. These findings could be explained by possible renal tubular origin or renal differentiation, at least in a subset, of nephrogenic adenomas.

Original languageEnglish
Pages (from-to)1224-1229
Number of pages6
JournalAmerican Journal of Surgical Pathology
Volume28
Issue number9
DOIs
StatePublished - Sep 2004

Fingerprint

Racemases and Epimerases
Coenzyme A
Adenoma
Urothelium
Kidney
Adenocarcinoma
Distal Kidney Tubule
Urethra
Keratins
Prostate
Prostatic Neoplasms
Molecular Weight
Research Personnel
Staining and Labeling
Wounds and Injuries

Keywords

  • AMACR
  • Immunohistochemistry
  • Nephrogenic adenoma
  • Renal tubule

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine

Cite this

Gupta, A., Wang, H. L., Policarpio-Nicolas, M. L., Tretiakova, M. S., Papavero, V., Pins, M. R., ... Yang, X. J. (2004). Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma. American Journal of Surgical Pathology, 28(9), 1224-1229. https://doi.org/10.1097/01.pas.0000131544.18266.a4

Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma. / Gupta, Anita; Wang, Hanlin L.; Policarpio-Nicolas, Maria Luisa; Tretiakova, Maria S.; Papavero, Veronica; Pins, Michael R.; Jiang, Zhong; Humphrey, Peter A.; Cheng, Liang; Yang, Ximing J.

In: American Journal of Surgical Pathology, Vol. 28, No. 9, 09.2004, p. 1224-1229.

Research output: Contribution to journalArticle

Gupta, A, Wang, HL, Policarpio-Nicolas, ML, Tretiakova, MS, Papavero, V, Pins, MR, Jiang, Z, Humphrey, PA, Cheng, L & Yang, XJ 2004, 'Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma', American Journal of Surgical Pathology, vol. 28, no. 9, pp. 1224-1229. https://doi.org/10.1097/01.pas.0000131544.18266.a4
Gupta A, Wang HL, Policarpio-Nicolas ML, Tretiakova MS, Papavero V, Pins MR et al. Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma. American Journal of Surgical Pathology. 2004 Sep;28(9):1224-1229. https://doi.org/10.1097/01.pas.0000131544.18266.a4
Gupta, Anita ; Wang, Hanlin L. ; Policarpio-Nicolas, Maria Luisa ; Tretiakova, Maria S. ; Papavero, Veronica ; Pins, Michael R. ; Jiang, Zhong ; Humphrey, Peter A. ; Cheng, Liang ; Yang, Ximing J. / Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma. In: American Journal of Surgical Pathology. 2004 ; Vol. 28, No. 9. pp. 1224-1229.
@article{3b779e8bff4e470e840f11a7c58b055f,
title = "Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma",
abstract = "Nephrogenic adenoma is a benign lesion composed of small glandular structures that develops along the urothelium with uncertain pathogenesis. Some investigators believe that nephrogenic adenoma develops by a metaplastic process in response to injury to the urothelium, while others believe that it arises from detached renal tubules. Nephrogenic adenoma may be present in the prostatic urethra and morphologically mimic prostatic adenocarcinoma. Alpha-methylacyl-coenzyme A racemase (AMACR), a recently identified prostate cancer marker, is typically negative in normal urothelium and prostatic glands, and positive in distal convoluted renal tubules in addition to prostatic adenocarcinomas. Therefore, evaluation of AMACR expression in nephrogenic adenoma will have significance in the pathologic diagnosis and in understanding pathogenesis of this lesion. We studied 38 nephrogenic adenomas by clinical, histologic, and immunohistochemical analyses for AMACR (P504S) and high molecular weight cytokeratin (34βE12). Twenty-two of 38 nephrogenic adenomas (58{\%}) demonstrated strong cytoplasmic positivity for AMACR, ranging from patchy, focal to diffuse staining. In addition, 16 of 26 (62{\%}) nephrogenic adenomas were negative for 34βE12. To our knowledge, this is one of the first report of a completely benign lesion, which can be found in the prostate, showing strong AMACR immunoreactivity. Our findings suggest using caution when interpreting positive AMACR immunostaining in prostatic specimens. These findings could be explained by possible renal tubular origin or renal differentiation, at least in a subset, of nephrogenic adenomas.",
keywords = "AMACR, Immunohistochemistry, Nephrogenic adenoma, Renal tubule",
author = "Anita Gupta and Wang, {Hanlin L.} and Policarpio-Nicolas, {Maria Luisa} and Tretiakova, {Maria S.} and Veronica Papavero and Pins, {Michael R.} and Zhong Jiang and Humphrey, {Peter A.} and Liang Cheng and Yang, {Ximing J.}",
year = "2004",
month = "9",
doi = "10.1097/01.pas.0000131544.18266.a4",
language = "English",
volume = "28",
pages = "1224--1229",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma

AU - Gupta, Anita

AU - Wang, Hanlin L.

AU - Policarpio-Nicolas, Maria Luisa

AU - Tretiakova, Maria S.

AU - Papavero, Veronica

AU - Pins, Michael R.

AU - Jiang, Zhong

AU - Humphrey, Peter A.

AU - Cheng, Liang

AU - Yang, Ximing J.

PY - 2004/9

Y1 - 2004/9

N2 - Nephrogenic adenoma is a benign lesion composed of small glandular structures that develops along the urothelium with uncertain pathogenesis. Some investigators believe that nephrogenic adenoma develops by a metaplastic process in response to injury to the urothelium, while others believe that it arises from detached renal tubules. Nephrogenic adenoma may be present in the prostatic urethra and morphologically mimic prostatic adenocarcinoma. Alpha-methylacyl-coenzyme A racemase (AMACR), a recently identified prostate cancer marker, is typically negative in normal urothelium and prostatic glands, and positive in distal convoluted renal tubules in addition to prostatic adenocarcinomas. Therefore, evaluation of AMACR expression in nephrogenic adenoma will have significance in the pathologic diagnosis and in understanding pathogenesis of this lesion. We studied 38 nephrogenic adenomas by clinical, histologic, and immunohistochemical analyses for AMACR (P504S) and high molecular weight cytokeratin (34βE12). Twenty-two of 38 nephrogenic adenomas (58%) demonstrated strong cytoplasmic positivity for AMACR, ranging from patchy, focal to diffuse staining. In addition, 16 of 26 (62%) nephrogenic adenomas were negative for 34βE12. To our knowledge, this is one of the first report of a completely benign lesion, which can be found in the prostate, showing strong AMACR immunoreactivity. Our findings suggest using caution when interpreting positive AMACR immunostaining in prostatic specimens. These findings could be explained by possible renal tubular origin or renal differentiation, at least in a subset, of nephrogenic adenomas.

AB - Nephrogenic adenoma is a benign lesion composed of small glandular structures that develops along the urothelium with uncertain pathogenesis. Some investigators believe that nephrogenic adenoma develops by a metaplastic process in response to injury to the urothelium, while others believe that it arises from detached renal tubules. Nephrogenic adenoma may be present in the prostatic urethra and morphologically mimic prostatic adenocarcinoma. Alpha-methylacyl-coenzyme A racemase (AMACR), a recently identified prostate cancer marker, is typically negative in normal urothelium and prostatic glands, and positive in distal convoluted renal tubules in addition to prostatic adenocarcinomas. Therefore, evaluation of AMACR expression in nephrogenic adenoma will have significance in the pathologic diagnosis and in understanding pathogenesis of this lesion. We studied 38 nephrogenic adenomas by clinical, histologic, and immunohistochemical analyses for AMACR (P504S) and high molecular weight cytokeratin (34βE12). Twenty-two of 38 nephrogenic adenomas (58%) demonstrated strong cytoplasmic positivity for AMACR, ranging from patchy, focal to diffuse staining. In addition, 16 of 26 (62%) nephrogenic adenomas were negative for 34βE12. To our knowledge, this is one of the first report of a completely benign lesion, which can be found in the prostate, showing strong AMACR immunoreactivity. Our findings suggest using caution when interpreting positive AMACR immunostaining in prostatic specimens. These findings could be explained by possible renal tubular origin or renal differentiation, at least in a subset, of nephrogenic adenomas.

KW - AMACR

KW - Immunohistochemistry

KW - Nephrogenic adenoma

KW - Renal tubule

UR - http://www.scopus.com/inward/record.url?scp=4344717687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344717687&partnerID=8YFLogxK

U2 - 10.1097/01.pas.0000131544.18266.a4

DO - 10.1097/01.pas.0000131544.18266.a4

M3 - Article

C2 - 15316323

AN - SCOPUS:4344717687

VL - 28

SP - 1224

EP - 1229

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 9

ER -